Home › Atherosclerosis › Washington
Atherosclerosis clinical trials in Washington
6 studies for Atherosclerosis are looking for participants at sites in Washington.
Cities in Washington
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
- Eastside Research Associates, LLC dba Era Health Research, Redmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07448038Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- ERA Health Research - CardioNow - Lynnwood, Lynnwood
- Eastside Research Associates, Redmond
- Rainier Clinical Research Center, Renton
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07157774A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
- Eastside Research Associates, Redmond
RecruitingPhase 3
Ages 45 to 80 · All sexes · Updated Sep 22, 2026 · NCT07613294Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- VA Puget Sound Healthcare System, Seattle
- Velocity Clinical Research - Spokane, Spokane
RecruitingPhase 3
Ages 45 to 99 · All sexes · Updated Sep 22, 2026 · NCT07037433A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Puyallup
- Research Site, Redmond
- Research Site, Renton
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT07000357Pelacarsen Roll-over Extension Program
- University of Washington, Seattle
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Jul 29, 2026 · NCT06875973From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.